IDH3A and central nervous system cancer: Patients with gliomas with gain-of-function isocitrate dehydrogenase (IDH) mutations generating the HDM oncometabolite/inhibitor 2-hydroxyglutarate (2HG), which also establishes a hypermethylator phenotype that stabilizes undifferentiated cellular states that may be targetable and expanded later by subsequent transforming mutations, are, on average, several years younger that those with wild-type IDH gliomas (Bleeker et al., 2010; Cohen et al., 2013; Popov et al., 2013; Dimitrov et al., 2015).